Brokers Offer Predictions for Dyadic International, Inc.’s Q2 2024 Earnings (NASDAQ:DYAI)

Dyadic International, Inc. (NASDAQ:DYAIFree Report) – Analysts at HC Wainwright issued their Q2 2024 earnings estimates for Dyadic International in a report issued on Monday, July 8th. HC Wainwright analyst V. Bernardino forecasts that the biotechnology company will post earnings per share of ($0.06) for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Dyadic International’s Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.11) EPS.

Dyadic International (NASDAQ:DYAIGet Free Report) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter. Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. The business had revenue of $0.33 million for the quarter. During the same quarter in the previous year, the business posted ($0.03) earnings per share.

Dyadic International Price Performance

Shares of NASDAQ DYAI opened at $1.38 on Wednesday. The stock has a fifty day moving average of $1.75 and a 200-day moving average of $1.60. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.29. Dyadic International has a fifty-two week low of $1.19 and a fifty-two week high of $2.67.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Callan Capital LLC acquired a new stake in Dyadic International, Inc. (NASDAQ:DYAIFree Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned 0.09% of Dyadic International at the end of the most recent quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

(Get Free Report)

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.

Further Reading

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with's FREE daily email newsletter.